By 2030, it is anticipated that the Malaysia infectious disease therapeutics market will reach a value of $275.12 Mn from $192.72 Mn in 2022, growing at a CAGR of 4.6% during 2022-2030. Infectious Disease Therapeutics in Malaysia is dominated by a few domestic pharmaceutical companies such as Pharmaniaga Berhad, Duopharma Biotech and Kotra Pharma. The Infectious Disease Therapeutics market in Malaysia is segmented into different therapeutic areas and different diseases type. The major factors affecting the Malaysia infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious disease treatment in various areas of Malaysia.
By 2030, it is anticipated that the Malaysia infectious disease therapeutics market will reach a value of $275.12 Mn from $192.72 Mn in 2022, growing at a CAGR of 4.6% during 2022-2030.
Malaysia, being an upper-middle-income, developing country, is a federation of 13 states and three federal territories in Southeast Asia. According to the World Factbook, Malaysia is extremely vulnerable to infectious illnesses. Food or waterborne infections include bacterial diarrhoea, hepatitis A and E, and typhoid fever.
Dengue fever is a vector-borne disease, and water-contact illnesses such as leptospirosis are frequent in Malaysia. Dengue fever is carried through the bite of pathogenic mosquitoes, and it affects a considerable proportion of Malaysia's population. from January to August 2021, the Malaysian government reported only a total of 16,565 dengue cases as opposed to 63,988 cases in 2020. The total number of dengue cases in the country has decreased by around 94%. Malaysia's government spends 4.1% of its GDP on healthcare.
Market Growth Drivers Analysis
The Malaysian Association for Tuberculosis Prevention (MAPTB) works hard to educate the public about TB prevention and to give financial assistance to diagnose and treat persons from high-risk categories. The COVID-19 pandemic has diverted attention away from the spread of other infectious illnesses around the world. However, the Malaysian government's fight against other infectious diseases has never halted. The government modified The Prevention and Manage of Infectious Diseases (Actions within Infected Local Areas) Regulations in March 2020 to better coordinate the measures it was adopted to control the COVID-19 pandemic and the transmission of other infectious diseases in Malaysia. These aspects could boost Malaysia's infectious disease therapeutics market.
Market Restraints
Malaysia used to receive considerable financial support from countries such as Japan, Denmark, and Germany in conjunction with the World Health Organization (WHO) until 1998. However, since 2000, the government has received little to no direct aid in the health sector. Many Malaysians may be unaware of the significance of infectious disease prevention and treatment, limiting demand for infectious disease medicines. Price competitiveness erosion in Malaysia due to rising labour costs might stymie corporate operations in the country. These factors may deter new entrants into the Malaysia infectious disease therapeutics market.
Key Players
December 2022: Pharmaniaga LifeScience, a wholly-owned subsidiary of Malaysia's leading pharmaceutical company, Pharmaniaga Berhad (Pharmaniaga), has committed to partner with BioNet-Asia on the development of a 6-in-1 Hexavalent Vaccine. The vaccine will provide Malaysian doctors with the best option for immunising children against six devastating childhood diseases. The programme will also help Malaysia achieve its objective of being vaccine self-sufficient by lowering reliance on importing life-saving vaccines and insulin from outside Malaysia. Furthermore, vaccine manufacture in-country will significantly improve vaccine security against future pandemic risks.
In Malaysia, the Ministry of Health (MOH) and the national health insurance programme, known as the MySalam plan, are in charge of the regulation and reimbursement of infectious disease medicines. The MySalam plan, which provides financial protection to eligible Malaysians diagnosed with certain infectious diseases, has a big influence on the reimbursement process for infectious disease medicines in Malaysia.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Mode of Treatment (Revenue, USD Billion):
By Applications (Revenue, USD Billion):
By Disease Type (Revenue, USD Billion):
By Target Organism (Revenue, USD Billion):
By End User (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
By 2030, it is anticipated that the Malaysia infectious disease therapeutics market will reach a value of $275.12 Mn from $192.72 Mn in 2022, growing at a CAGR of 4.6% during 2022-2030.
In Malaysia, the regulation and reimbursement of infectious disease therapeutics are primarily overseen by the Ministry of Health (MOH) and the national health insurance program, the MySalam scheme.
Infectious Disease Therapeutics in Malaysia is dominated by domestic pharmaceutical companies such as Pharmaniaga Berhad, Duopharma Biotech and Kotra Pharma.